-
Product Insights
Net Present Value Model: Doptelet
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model Doptelet Drug Details Avatrombopag maleate (Doptelet/...
-
Sector Analysis
Respiratory Syncytial Virus – Epidemiology Forecast to 2030
The Respiratory Syncytial Virus (RSV) prophylactic population in the eight major markets (*8MM) is projected to increase from over 14.55 million cases in 2020 to 15.64 million in 2030, with an annual growth rate (AGR) of 0.75%. This report estimates that in 2030, the US will have the highest number of prophylactic eligible individuals across the 8MM, with over 6.53 million individuals. Spain will have the lowest number of prophylactic eligible individuals with approximately 0.66 million individuals. In the *5EU,...
-
Sector Analysis
Respiratory Syncytial Virus Prophylaxis – Global Drug Forecast and Market Analysis to 2030
Respiratory syncytial virus (RSV) is a common respiratory infection that most children will be infected with by the time they are two years old. RSV infection generally causes mild flu-like symptoms, which can include a runny nose, lowered appetite, fever, coughing, and/or sneezing. Irritability and difficulty breathing may be the only symptoms shown by very young infants with RSV. RSV is a viral infection that is transmitted through contact with droplets in the air or on surfaces like doorknobs, tabletops,...
-
Sector Analysis
Respiratory Syncytial Virus – Opportunity Analysis and Forecasts to 2028
Human respiratory syncytial virus (RSV) is an enveloped, single-stranded, negative-sense RNA orthopneumovirus belonging to the family of Paramyxoviridae. The virus was discovered in 1956, first as an isolate from a laboratory chimpanzee displaying symptoms of the common cold, and later from infants suffering from respiratory disease. The most common clinical scenario for RSV is an upper respiratory tract infection which is typically mild and self-limiting. However, RSV is the leading cause of lower respiratory tract infections (LRTIs) in infants, with...
-
Sector Analysis
Respiratory Syncytial Virus – Epidemiology Forecast to 2028
Respiratory syncytial virus (RSV) is a common respiratory infection that most children will be infected with by the time they are two years old. In healthy individuals RSV usually self-resolves within a week or two without need for significant therapeutic intervention. In preterm and very young infants, the elderly, or those with otherwise compromised immune systems, however, RSV can cause severe illness or death. It has been estimated that up to 30 million episodes of RSV-related lower respiratory infection occur...
-
Sector Analysis
Respiratory Syncytial Virus – Epidemiology Forecast in Asia-Pacific Markets to 2028
Respiratory syncytial virus (RSV) is a common respiratory infection that most children will be infected with by the time they are two years old. In healthy individuals RSV usually self-resolves within a week or two without need for significant therapeutic intervention. In preterm and very young infants, the elderly, or those with otherwise compromised immune systems, however, RSV can cause severe illness or death. It has been estimated that up to 30 million episodes of RSV-related lower respiratory infection occur...
-
Sector Analysis
OpportunityAnalyzer: Respiratory Syncytial Virus (RSV) – Opportunity Analysis and Forecasts to 2024
Human respiratory syncytial virus (RSV) is an enveloped, single-stranded, negative-sense ribonucleic acid (RNA) pneumovirus belonging to the family of Paramyxoviridae. The virus was discovered in 1956, first as an isolate from a laboratory chimpanzee displaying symptoms of the common cold, and later from infants suffering from respiratory disease. RSV can cause upper respiratory tract infections (the common cold) and is the most important cause of lower respiratory tract infections, such as bronchiolitis and pneumonia, in infants. RSV is also an...
-
Sector Analysis
Respiratory Syncytial Virus (RSV) – Forecast in Asia-Pacific Markets to 2028
Human respiratory syncytial virus (RSV) is an enveloped, single-stranded, negative-sense RNA orthopneumovirus belonging to the family of Pneumoviridae. The virus was discovered in 1956, first as an isolate from a laboratory chimpanzee displaying symptoms of the common cold, and later from infants suffering from respiratory disease. The most common clinical scenario for RSV is an upper respiratory tract infection which is typically mild and self-limiting. However, RSV is the leading cause of lower respiratory tract infections (LRTIs) in infants, with...